Abstract
BackgroundSerum drug levels and anti-drug antibodies (ADAb) impact the therapeutic effectiveness of most TNF-inhibitors. Possible differences in immunogenicity profile and pharmacokinetics across biosimilar and originator TNFi are still to be...
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have